SymBio Pharmaceuticals Limited
SYMQY
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.98B
Close$
Share Statistics
| Market cap | $2.98 Billion |
|---|---|
| Enterprise Value | $2.83 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-99.73 |
| Beta | 0.53 |
| Outstanding Shares | 76,342,991 |
Return
| Return on Equity | 1054.86% |
|---|---|
| Return on Assets | -322.33% |
| Return on Invested Capital | 1060.53% |
Valuation & Multiples
| P/E Ratio | -0.54 |
|---|---|
| PEG | -3.03 |
| Price to Sales | 0.04 |
| Price to Book Ratio | -0.07 |
| Enterprise Value to Revenue | 2.48 |
| Enterprise Value to EBIT | -0.47 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | -1.43 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About SymBio Pharmaceuticals Limited
91 employees
CEO: Fuminori Yoshida SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, ...